[
    [
        {
            "time": "2019-04-22",
            "original_text": "Health Care Sector Update for 04/22/2019: ISRG, AXGN, LLY, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "Health Care Sector",
                    "LLY",
                    "JNJ",
                    "PFE"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Health Care Sector Update for 04/22/2019: ISRG, AXGN, LLY, JNJ, PFE, ABT, MRK, AMGN",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Falls",
                    "Positive Phase 3",
                    "Taltz"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Update: Eli Lilly (NYSE:LLY) Stock Gained 97% In The Last Five Years",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Stock Gained",
                    "97%",
                    "Five Years"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Update: Eli Lilly (NYSE:LLY) Stock Gained 97% In The Last Five Years",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Pfizer",
                    "Non-Opioid",
                    "Safety",
                    "Efficacy"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Eli Lilly stock down 3.4% despite positive Phase 3 findings for Taltz",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "stock down",
                    "Phase 3",
                    "Taltz"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly stock down 3.4% despite positive Phase 3 findings for Taltz",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",
            "features": {
                "keywords": [
                    "Lilly",
                    "Positive Top-Line",
                    "COAST-X",
                    "Taltz",
                    "Spondyloarthritis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-22",
            "original_text": "Lilly and Avidity Biosciences Announce Licensing and Research Collaboration",
            "features": {
                "keywords": [
                    "Lilly",
                    "Avidity Biosciences",
                    "Licensing",
                    "Research Collaboration"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly and Avidity Biosciences Announce Licensing and Research Collaboration",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]